Table 3:

Odd Ratios (ORs) associated with development of SMN based on univariate analysis of matched sets

		Univariate Analysis
	N matched sets	OR	95% CI	p value
BMI Z-Score at Diagnosis	59	1.30	1.02–1.66	0.038
BMI Category at Diagnosis	59
Normal/Underweight		1.00	Ref	-
Overweight		1.24	0.56–2.74	0.60
Obese		2.58	1.05–6.38	0.039
Global Null Hypothesis Test		-	-	0.12
BMI Z-Score EOT	50	1.06	0.82–1.36	0.68
BMI Category at EOT	50
Normal/Underweight		1.00	Ref	-
Overweight		0.40	0.10–1.46	0.16
Obese		2.37	0.93–6.06	0.071
Global Null Hypothesis Test		-	-	0.033
BMI Category Change Diagnosis to EOT	50
Not Obese to Not Obese		1.00	Ref	-
Not Obese to Obese		1.98	0.60–6.56	0.26
Obese to Not Obese		1.34	0.20–8.90	0.76
Obese to Obese		4.24	1.35–13.34	0.014
Global Null Hypothesis Test		-	-	0.09
Suspected/Confirmed Syndrome at Primary Cancer	59
No		1.00	Ref	-
Yes		2.86	0.75–10.98	0.12
Race/Ethnicity	59
Non-Latino white		1.00	Ref	-
Black, Latino white, Asian/Pacific Islander, or other		0.68	0.30–1.54	0.36
Radiation Exposure (Progression/Relapse)	59
No		1.00	Ref	-
Yes		1.61	0.53–4.89	0.40
Cumulative Cyclophosphamide Equivalent Dose (CED)	59
0		1.00	Ref	-
1–4000 mg/m2		0.31	0.07–1.33	0.12
4001+ mg/m2		0.58	0.19–1.78	0.34
Global Null Hypothesis Test		-	-	0.29
Cumulative Anthracycline Dose	59
0		1.00	Ref	-
1–169 mg/m2		1.78	0.28–11.43	0.54
170+ mg/m2		2.16	0.31–15.16	0.44
Global Null Hypothesis Test		-	-	0.73
Cumulative Epipodophyllotoxin Dose	59
0		1.00	Ref	-
1–1800 mg/m2		2.95	1.00–8.76	0.051
1801+ mg/m2		1.99	0.68–5.83	0.21
Global Null Hypothesis Test		-	-	0.13
Platinum-based Chemotherapy Exposure	59
No		1.00	Ref	-
Yes		1.23	0.38–4.01	0.73

^*no significant interactions between sex and BMI Z-score at diagnosis, sex and each predictor, BMI category and each predictor, follow-up time and BMI Z-score at diagnosis; SMN=second malignant neoplasm; EOT=end of therapy.